Sematid 3

• Type 2 diabetes mellitus (as an adjunct to diet and exercise)
• Reduction of major adverse cardiovascular events in type 2 diabetes with established cardiovascular disease
• Chronic weight management in obesity (BMI ≥30) or overweight (BMI ≥27 with weight-related comorbidity)

Diabetes (Injection):

• Starting: 0.25 mg once weekly for 4 weeks
• Maintenance: 0.5 mg once weekly after 4 weeks
• Additional control: 1 mg once weekly if needed

Diabetes (Tablet):

• Starting: 3 mg/day for 30 days
• Maintenance: 7 mg/day
• Additional control: 14 mg/day

Obesity (Injection):

• Starting: 0.25 mg once weekly for 4 weeks
• Titration: 0.5→1.0→1.7→2.4 mg (each for 4 weeks)
• Maintenance: 2.4 mg once weekly

Common Side Effects (>10%):

• Nausea (15.8-20.3%)
• Hypoglycemia with adjunctive therapy (16.7-29.8%)

1-10%:

• Vomiting (5-9.2%), Diarrhea (8.5-8.8%)
• Abdominal pain (5.7-7.3%), Constipation (3.1-5%)
• Dyspepsia, flatulence, GERD

Rare:

• Anaphylaxis, pancreatitis

• Risk of thyroid C-cell tumors (MTC); contraindicated in personal/family history of MTC or MEN 2
• Do not use in type 1 diabetes or diabetic ketoacidosis
• Monitor for signs of pancreatitis
• Caution in history of diabetic retinopathy
• Monitor renal function with severe GI reactions
• Do not use during pregnancy; discontinue 2 months before planned pregnancy